Guggenheim downgraded Iveric bio to Neutral from Buy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE:
- Iveric Bio (NASDAQ:ISEE) Sold for $5.9B
- Astellas to acquire Iveric Bio for $40 per share in cash
- Astellas Enters into Definitive Agreement to Acquire Iveric Bio
- IVERIC bio call volume above normal and directionally bullish
- Iveric bio announces findings from exploratory analyses of data for ACP
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue